A decrease in the delivery of triglyceride-enriched very low-density lipoprotein (VLDL) to the liver by downregulating VLDL receptor expression has also been described as a mechanism by which FGF21 treatment lowers hepatic steatosis (124) (125). The gene discussed is FGF21; the disease is fatty liver disease.